MUMBAI, Feb 22: Pharma major, Lupin on Saturday said that it has received establishment inspection report (EIR) from the US Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey, USA.
The USFDA inspected the facility from January 27, 2025 to January 31, 2025.
Nilesh Gupta, managing director, Lupin, said, “We are very pleased to have received the EIR for our Somerset facility. This milestone underscores our commitment to upholding the highest standards of quality and compliance, solidifying our position as a leading pharmaceutical manufacturer.” (UNI)
Follow our WhatsApp channel
